MYEOV, also named as OCIM, was originally isolated by the application of the NIH/3T3 tumorigenicity assay with DNA from a gastric carcinoma. It is a prognostic factor for patients with multiple myeloma, in part through a role of MYEOV in the control of MMC proliferation. MYEOV is a candidate oncogene activated in the amplification core located proximal toCCND1.
myeloma overexpressed (in a subset of t(11;14) positive multiple myelomas); myeloma overexpressed gene (in a subset of t(11;14) positive multiple myelomas); Myeloma-overexpressed gene protein; Oncogene in multiple myeloma
Searching for an antibody we don't offer? We make custom antibodies for specific targets, species and applications.
More than 18,000 custom antibodies created so far.Talk to a specialist now